174 related articles for article (PubMed ID: 21421726)
21. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).
Hodé Y; Reimold M; Demazières A; Reischl G; Bayle F; Nuss P; Hameg A; Dib M; Macher JP
Psychopharmacology (Berl); 2005 Jul; 180(2):377-84. PubMed ID: 15948013
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography.
Nakazawa S; Yokoyama C; Nishimura N; Horisawa T; Kawasaki A; Mizuma H; Doi H; Onoe H
Psychopharmacology (Berl); 2013 Jan; 225(2):329-39. PubMed ID: 22868411
[TBL] [Abstract][Full Text] [Related]
23. The use of healthy volunteers instead of patients to inform drug dosing studies: a [¹¹C]raclopride PET study.
Kim E; Howes OD; Kim BH; Yu KS; Jeong JM; Lee JS; Kim SJ; Jang IJ; Park JS; Kim YG; Shin SG; Turkheimer FE; Kapur S; Kwon JS
Psychopharmacology (Berl); 2011 Oct; 217(4):515-23. PubMed ID: 21503604
[TBL] [Abstract][Full Text] [Related]
24. Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Tauscher-Wisniewski S; Kasper S
Psychopharmacology (Berl); 2002 Jun; 162(1):42-9. PubMed ID: 12107616
[TBL] [Abstract][Full Text] [Related]
25. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
[TBL] [Abstract][Full Text] [Related]
26. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
Bressan RA; Erlandsson K; Jones HM; Mulligan RS; Ell PJ; Pilowsky LS
J Clin Psychopharmacol; 2003 Feb; 23(1):5-14. PubMed ID: 12544369
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and time-course of D(2) receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients.
Catafau AM; Penengo MM; Nucci G; Bullich S; Corripio I; Parellada E; García-Ribera C; Gomeni R; Merlo-Pich E;
J Psychopharmacol; 2008 Nov; 22(8):882-94. PubMed ID: 18308793
[TBL] [Abstract][Full Text] [Related]
28. ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.
Davis RE; Vanover KE; Zhou Y; Brašić JR; Guevara M; Bisuna B; Ye W; Raymont V; Willis W; Kumar A; Gapasin L; Goldwater DR; Mates S; Wong DF
Psychopharmacology (Berl); 2015 Aug; 232(15):2863-72. PubMed ID: 25843749
[TBL] [Abstract][Full Text] [Related]
29. Modeling of brain D2 receptor occupancy-plasma concentration relationships with a novel antipsychotic, YKP1358, using serial PET scans in healthy volunteers.
Lim KS; Kwon JS; Jang IJ; Jeong JM; Lee JS; Kim HW; Kang WJ; Kim JR; Cho JY; Kim E; Yoo SY; Shin SG; Yu KS
Clin Pharmacol Ther; 2007 Feb; 81(2):252-8. PubMed ID: 17259948
[TBL] [Abstract][Full Text] [Related]
30. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
31. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
[TBL] [Abstract][Full Text] [Related]
33. In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients.
Barnas C; Quiner S; Tauscher J; Hilger E; Willeit M; Küfferle B; Asenbaum S; Brücke T; Rao ML; Kasper S
Psychopharmacology (Berl); 2001 Sep; 157(3):236-42. PubMed ID: 11605078
[TBL] [Abstract][Full Text] [Related]
34. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.
Meisenzahl EM; Dresel S; Frodl T; Schmitt GJ; Preuss UW; Rossmüller B; Tatsch K; Mager T; Hahn K; Möller HJ
J Psychopharmacol; 2000; 14(4):364-70. PubMed ID: 11198054
[TBL] [Abstract][Full Text] [Related]
35. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples.
Chernet E; Martin LJ; Li D; Need AB; Barth VN; Rash KS; Phebus LA
Life Sci; 2005 Dec; 78(4):340-6. PubMed ID: 16139310
[TBL] [Abstract][Full Text] [Related]
36. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
[TBL] [Abstract][Full Text] [Related]
37. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia.
Vernaleken I; Siessmeier T; Buchholz HG; Härtter S; Hiemke C; Stoeter P; Rösch F; Bartenstein P; Gründer G
Int J Neuropsychopharmacol; 2004 Dec; 7(4):421-30. PubMed ID: 15683553
[TBL] [Abstract][Full Text] [Related]
38. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride.
Mukherjee J; Christian BT; Narayanan TK; Shi B; Mantil J
Neuropsychopharmacology; 2001 Oct; 25(4):476-88. PubMed ID: 11557161
[TBL] [Abstract][Full Text] [Related]
40. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study.
Gefvert O; Lundberg T; Wieselgren IM; Bergström M; Långström B; Wiesel F; Lindström L
Eur Neuropsychopharmacol; 2001 Apr; 11(2):105-10. PubMed ID: 11313155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
